Inmolecule Nanotech SA

As of December 31, 2024, Inmolecule Nanotech SA has 7.50M shares outstanding.

As of December 31, 2024, Inmolecule Nanotech SA maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.04, indicating elevated leverage, while an interest coverage ratio of 2.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2024, Inmolecule Nanotech SA posted a negative return on equity (ROE) of -2.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.70, reflecting losses generated across the asset base. The company generates approximately 25,393.69 in revenue per employee across its workforce of 78.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.15 indicates how many times Inmolecule Nanotech SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2024, Inmolecule Nanotech SA generated 1.98M in revenue and converted that into -227,740.02 in net income, yielding earnings per share of -0.03. EBITDA reached 35,246.30, while operating income came in at -217,932.55.

As of December 31, 2024, Inmolecule Nanotech SA holds 87,301.23 in cash and equivalents against 1.94M in total debt, resulting in a net debt position of 1.85M. Total book value stands at 7.39M, with working capital of 3.17M providing operational flexibility.

Over the twelve months ended December 31, 2024, Inmolecule Nanotech SA posted a gross margin of 79.87, reflecting its pricing power and cost economics. The operating margin of -11.00 and net profit margin of -11.50 provide insight into operational efficiency.